Trial Profile
Study to evaluate the pharmacokinetic properties of tamibarotene in relapse or refractory pediatric solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2018
Price :
$35
*
At a glance
- Drugs Tamibarotene (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 01 Oct 2018 New trial record
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development